Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCT510 vs bevacizumab plus paclitaxel/carboplatin in non-squamous NSCLC
CTR20181634Phase 3Completed
- Sponsor
- Shenzhou Cell Engineering Co., Ltd.
- Start
- Dec 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of SCT510A in Non-small cell lung cancer (NS-NSCLC), sponsored by Shenzhou Cell Engineering Co., Ltd.. Started Dec 2018; status: completed.
02
Drugs
SCT510A
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on CTR20181634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20181634.